Literature DB >> 27815407

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Béatrice Pignolet1, Nicholas Schwab1, Tilman Schneider-Hohendorf1, Florence Bucciarelli1, Damien Biotti1, Delphine Averseng-Peaureaux1, Olivier Outteryck1, Jean-Claude Ongagna1, Jérôme de Sèze1, Bruno Brochet1, Jean-Christophe Ouallet1, Marc Debouverie1, Sophie Pittion1, Gilles Defer1, Nathalie Derache1, Patrick Hautecoeur1, Ayman Tourbah1, Pierre Labauge1, Giovanni Castelnovo1, Pierre Clavelou1, Eric Berger1, Jean Pelletier1, Audrey Rico1, Hélène Zéphir1, David Laplaud1, Sandrine Wiertlewski1, William Camu1, Eric Thouvenot1, Olivier Casez1, Thibault Moreau1, Agnès Fromont1, Sandra Vukusic1, Caroline Papeix1, Patrick Vermersch1, Manuel Comabella1, Christine Lebrun-Frenay1, Heinz Wiendl1, David Brassat2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27815407     DOI： 10.1212/WNL.0000000000003401

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

2.  Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.

Authors:  Nicolás Fissolo; Beatrice Pignolet; Jordi Rio; Patrick Vermersch; Aurélie Ruet; Jerome deSèze; Pierre Labauge; Sandra Vukusic; Caroline Papeix; Laurent Martinez-Almoyna; Ayman Tourbah; Pierre Clavelou; Thibault Moreau; Jean Pelletier; Christine Lebrun-Frenay; Bertrand Bourre; Gilles Defer; Xavier Montalban; David Brassat; Manuel Comabella
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-26

3.  The effect of disease modifying therapies on CD62L expression in multiple sclerosis.

Authors:  Margarete Maria Voortman; Paul Greiner; Daniel Moser; Martin Helmut Stradner; Winfried Graninger; Adrian Moser; Bernd Haditsch; Christian Enzinger; Siegrid Fuchs; Franz Fazekas; Johannes Fessler; Michael Khalil
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-09-20

Review 4.  The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

Authors:  Barry A Singer
Journal:  Ther Adv Neurol Disord       Date:  2017-06-23       Impact factor: 6.570

Review 5.  The use of natalizumab for multiple sclerosis.

Authors:  Rachel Brandstadter; Ilana Katz Sand
Journal:  Neuropsychiatr Dis Treat       Date:  2017-06-28       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.